<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01803282</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-296-0101</org_study_id>
    <nct_id>NCT01803282</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study in Solid Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, sequential dose-escalation, and expansion study to
      evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GS-5745 alone
      and in combination with chemotherapy.

      The study consists of 2 parts (Parts A and B). Participants can only qualify for and
      participate in 1 part.

      Part A is a sequential dose escalation to determine the maximum tolerated dose of GS-5745 in
      participants with advanced solid tumors that are refractory to or intolerant to standard
      therapy or for which no standard therapy exists. In Part A, participants will receive
      GS-5745 only. Part A will consist of between 12 to 48 participants.

      Part B is a dose expansion to obtain additional safety and tolerability data for GS-5745 in
      participants with advanced pancreatic adenocarcinoma, lung adenocarcinoma, lung squamous
      cell carcinoma, esophagogastric adenocarcinoma, colorectal cancer, or breast cancer. In Part
      B, participants will receive GS-5745 in combination with standard-of-care chemotherapy. Part
      B will consist of between 115 to 265 participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety as evaluated by incidence of AEs, assessment of clinical laboratory test findings, physical examination, 12-lead ECG, and vital signs measurements</measure>
    <time_frame>Baseline to completion of follow up evaluation. If follow up evaluation is not completed, baseline to date of first documented progression or date of death from any cause, whichever came first</time_frame>
    <safety_issue>No</safety_issue>
    <description>AEs that begin on or after the first study drug administration and within 30 days after last study drug administration will be summarized by dose level (Part A) and tumor type (Part B).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">343</enrollment>
  <condition>Tumors</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Esophagogastric Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GS-5745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-5745 by intravenous (IV) infusion over approximately 30 minutes every 2 weeks on Days 1 and 15 of each 28-day treatment cycle or every 3 weeks on Day 1 of each 21-day treatment cycle (NSCLC group only).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-5745 by IV infusion every 2-3 weeks in combination with chemotherapy as follows:
Pancreatic adenocarcinoma, esophagogastric adenocarcinoma, CRC, and breast cancer: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Non Small Cell Lung Carcinoma (NSCLC): Administered intravenously on Day 1 of each 21-day treatment cycle
In Part B, GS-5745 will be given in combination with one of the following chemotherapy regimens:
Pancreatic adenocarcinoma: gemcitabine and nab-paclitaxel
NSCLC:
lung adenocarcinoma: carboplatin and pemetrexed
lung squamous cell carcinoma: carboplatin and paclitaxel
Esophagogastric adenocarcinoma: mFOLFOX6 (leucovorin+oxaliplatin+5-FU)
First-line colorectal cancer (CRC): mFOLFOX6 and bevacizumab
Second-line colorectal cancer: FOLFIRI (leucovorin+irinotecan+5-FU) and bevacizumab
Breast cancer: Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5745</intervention_name>
    <description>GS-5745 administered intravenously</description>
    <arm_group_label>GS-5745</arm_group_label>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered intravenously on Day 1 of each 21-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed administered intravenously on Day 1 of each 21-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin administered intravenously on Days 1 and 15 of each 28-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin administered intravenously on Days 1 and 15 of each 28-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU administered intravenously on Days 1 and 15 of each 28-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab administered intravenously on Days 1 and 15 of each 28-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan administered intravenously on Days 1 and 15 of each 28-day treatment cycle</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)</description>
    <arm_group_label>GS-5745 with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A: histologically or cytologically confirmed advanced malignant solid tumor that
             is refractory to or intolerant of standard therapy or for which no standard therapy
             is available

          -  Part B: Pancreatic Adenocarcinoma

               -  Presence of histologically confirmed inoperable locally advanced or metastatic
                  pancreatic adenocarcinoma

          -  Part B: NSCLC

               -  Stage IIIB with malignant pleural effusion/pleural seeding or stage IV
                  histologically confirmed NSCLC

               -  Absence of known epidermal growth factor receptor (EGFR) mutation

               -  Absence of known translocation or inversion events involving the ALK gene locus
                  (resulting in EML4-ALK fusion)

          -  Part B: Esophagogastric Adenocarcinoma:

               -  Histologically confirmed inoperable advanced gastric adenocarcinoma (including
                  adenocarcinoma of the gastrooesophageal junction) or relapsed gastric
                  adenocarcinoma

               -  Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or
                  metastatic lesion)

          -  Part B: First-Line Colorectal Cancer

               -  Histologically confirmed inoperable advanced adenocarcinoma of the colon or
                  rectum

               -  Radiographically measureable disease

               -  No prior cytotoxic chemotherapy to treat their metastatic disease

          -  Part B: Second-Line Colorectal Cancer

               -  Histologically confirmed inoperable advanced adenocarcinoma of the colon or
                  rectum

               -  Radiographically measureable disease

               -  Received first-line combination therapy containing oxaliplatin and
                  fluoropyrimidine with or without bevacizumab for metastatic disease with
                  documented evidence of disease progression during or after treatment completion

          -  Part B: Breast Cancer

               -  Histologically or cytologically confirmed metastatic breast cancer

               -  Radiographically measureable disease

               -  Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant
                  chemotherapy is allowed

               -  Treatment with weekly single-agent paclitaxel is appropriate in the opinion of
                  the treating physician

               -  HER-2 negative tumor (primary tumor or metastatic lesion)

          -  Adequate organ function

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Individuals with known central nervous system (CNS) metastases, unless metastases are
             treated and stable and the individual does not require systemic steroids

          -  Myocardial infarction, symptomatic congestive heart failure, unstable angina, or
             serious uncontrolled cardiac arrhythmia within the last 6 months

          -  Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone
             therapy for breast or prostate cancer is permitted
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Vosganian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Oncology Hematology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia (Pat) Shannon</last_name>
      <phone>480-860-5000</phone>
      <email>pshannon@azpoh.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Marquez</last_name>
      <phone>661-862-7122</phone>
      <email>vmarquez@cbccusa.com</email>
    </contact>
    <investigator>
      <last_name>Ravindranath Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Diego Pacific Oncology and Hematology Associates, Inc.</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Cox</last_name>
      <phone>760-452-3909</phone>
      <email>bcox@ccare.com</email>
    </contact>
    <investigator>
      <last_name>Alberto Bessudo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Eng</last_name>
      <phone>415-600-1775</phone>
      <email>EngB@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>Ari Baron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Yonemoto</last_name>
      <phone>310-582-4069</phone>
      <email>lyonemoto@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev Wainberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Akins</last_name>
      <phone>941-377-9993</phone>
      <phone_ext>313</phone_ext>
      <email>aakins@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Thorne</last_name>
      <phone>574-364-2439</phone>
      <email>tthorne@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Alexander Starodub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Garrison</last_name>
      <phone>646-962-9344</phone>
      <email>keg2015@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Manish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John McClure</last_name>
      <phone>615-524-4084</phone>
      <email>John.McClure@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea Henrichs</last_name>
      <phone>615-936-3698</phone>
      <email>chelsea.henrichs@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Jordan Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Stafford</last_name>
      <phone>214-648-4260</phone>
      <email>jay.stafford@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Saad Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Quinsey</last_name>
      <phone>253-428-8738</phone>
      <email>squinsey@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Chaves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 7, 2016</lastchanged_date>
  <firstreceived_date>February 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Pancreatic</keyword>
  <keyword>Esophagogastric</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Breast</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
